SLU-PP-332

SLU-PP-332 100x10mg

Manufacturer: Black Labs

Package: 100 tablets

Common Names: SLU-PP-332, SLU PP-332, Rev-Erb Agonist

Info: SLU-PP-332 is an experimental small-molecule compound investigated for its activity at the Rev-Erb family of nuclear receptors, particularly Rev-Erbα and Rev-Erbβ. These receptors play important roles in circadian rhythm regulation, mitochondrial function, energy metabolism, and cellular metabolic signaling. Preclinical research has attracted interest in SLU-PP-332 because of its potential to influence pathways associated with oxidative metabolism, mitochondrial activity, and energy expenditure.

Effects

SLU-PP-332 has been investigated for its ability to activate Rev-Erb receptors and influence metabolic pathways involved in cellular energy utilization. Experimental studies have examined its effects on mitochondrial function, oxidative metabolism, and energy expenditure, particularly in skeletal muscle and other metabolically active tissues.

Research has also explored its potential exercise-mimetic properties. In preclinical models, modulation of Rev-Erb signaling has been associated with changes in metabolic gene expression and pathways involved in oxidative capacity. These findings remain experimental and should not be interpreted as evidence of established effects in humans.

Side Effects

Because SLU-PP-332 is an investigational compound, its complete safety profile in humans has not been established. Potential adverse effects, long-term risks, effects on cardiovascular or metabolic function, and interactions with other substances remain insufficiently characterized. Findings from animal and laboratory studies cannot be directly extrapolated to human safety or efficacy.

Dosage Range and Duration of Use

There is currently no established or clinically validated human dosage for SLU-PP-332. In preclinical animal research, experimental rodent protocols typically investigate oral or intraperitoneal dosages ranging from 25 mg/kg to 50 mg/kg administered once or twice daily over treatment durations of 2 to 6 weeks. Human research protocols remain non-standardized, though preliminary anecdotal discussions outline trial ranges from 10 mg to 50 mg per day. The appropriate duration and safe long-term exposure parameters for humans have not been established.  

Combination with Other Drugs

The interaction profile of SLU-PP-332 with prescription medications, supplements, or other pharmacologically active compounds has not been adequately established. Since the compound may influence nuclear receptor signaling and metabolic pathways, potential interactions cannot currently be predicted with sufficient reliability. Further pharmacological and clinical research is required to characterize its metabolism, safety profile, and possible drug interactions.